Advertisement

Topics

HARVEY NASH GROUP Company Profile

07:47 EDT 20th June 2018 | BioPortfolio

Harvey Nash was founded in London in 1988. David Higgins, the current Executive Vice Chairman, was one of the original founders and still has a sizeable financial stake in the company. Early on, the management broadened the Group’s geographical coverage and increased the range of services, recognising the value this would add to the business in the longer term.

An IPO in April 1997 facilitated a fresh injection of capital into the business, fast tracking expansion into Europe, the USA and Asia. This was achieved through a mix of acquisitions and organic growth.

Today, Harvey Nash holds a unique position as the only truly global IT recruitment business listed on the London Stock Exchange with over 3,000 employees and contractors working across 28 offices worldwide

Location

13 Bruton Street
London
London
W1J 6QA
United Kingdom

Contact

Phone: 44 (0)20 7333 0033
Fax: 44 (0)20 7333 0032
Email: info@harveynash.com


News Articles [697 Associated News Articles listed on BioPortfolio]

Texas Flood: Researchers Compare Pollution Levels before and after Hurricane Harvey

In the laboratory, researchers extracted organic compounds from the pre-Harvey dust and post-Harvey soil samples and analyzed them using gas chromatography

Según la encuesta Harvey Nash/KPMG CIO, los directorios de empresas se apresuran a aumentar ...

- Las amenazas de ciberdelitos alcanzan su máximo histórico - Solo un quinto de los líderes de TI del mundo están bien preparados para un Read more...

The Race To Find A Treatment For NASH

Although there are a number of investigational NASH therapies in various stages of development, there is no approved drug yet for this silent killer. However, the fact that the race to develop an effe...

Harvey Investment Co Has Decreased Its Idex (IEX) Stake; Mangrove...

Harvey Investment Co Llc decreased Idex Corp stake by 9.62% reported in 2017Q4 SEC filing. Harvey Investment Co Llc sold 11,775 shares as Idex Corp 's stock rose 7.15%.

Data and Cybersecurity Investments Ramp Up as Threats Reach All-Time High

Rajiv LeventhalCompanies are quickly ramping up investment in data and cybersecurity as they look to become more compliant with new data privacy protection and security regulations—and to avoid high...

Hurricane Harvey: Dutch-Texan Research Shows Most Fatalities Occurred outside Flood Zones

Harvey, one of the costliest storms in US history, hit southeast Texas on 25 August 2017 causing unprecedented flooding and killing dozens

[Comment] FGF-19 agonism for NASH: a short study of a long disease

Non-alcoholic steatohepatitis (NASH) has emerged as the most common cause of liver disease worldwide and is on a trajectory to become the most common indication for liver transplantation.1,2 Interest ...

Startup Terns Secures Three NASH Assets From Eli Lilly

The $40 billion market for nonalcoholic steatohepatitis (NASH) is becoming a little more crowded. Less than one year after launching Terns Pharmaceuticals acquired exclusive licensing rights to three ...

PubMed Articles [1943 Associated PubMed Articles listed on BioPortfolio]

Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model.

The incidence of nonalcoholic steatohepatitis (NASH) is increasing. The pathophysiological mechanisms of NASH and the sequence of events leading to hepatic fibrosis are incompletely understood. The ai...

Nonalcoholic steatohepatitis in posttransplantation liver: Review article.

Nonalcoholic steatohepatitis (NASH) associated or not with cirrhosis is the third leading indication for liver transplantation (LT) around the world. After transplants, NASH has a high prevalence and ...

Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH.

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) can advance, if untreated, to liver fibrosis, cirrhosis, hepatocellular carcinoma, liver failure and liver-related de...

The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom.

Nonalcoholic fatty liver disease (NAFLD) is a common liver disorder that can be divided into benign steatosis or nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). Elastography a...

A long-acting FGF21 alleviates hepatic steatosis and inflammation in NASH mice partly through an FGF21- adiponectin- IL17A axis.

NASH is the most severe form of NAFLD and is a serious public health problem around the world. There are currently no approved treatments for NASH. FGF21 has recently emerged as a promising drug candi...

Clinical Trials [3844 Associated Clinical Trials listed on BioPortfolio]

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity. CP-945598 is also being considered as a potential treat...

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

The primary objective of this study is the proof of mechanism and support of dose finding, together with the safety evaluation in patients with clinical evidence of NASH. To gain further ...

A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)

TARGET-NASH is a longitudinal observational cohort study of patients being managed for NAFLD or NASH in usual clinical practice. TARGET-NASH will create a research registry of patients wit...

Protocol for the Assessment of Variability in Histology and Gene Expression in Bariatric Surgery Patients.

It is known that a vast majority of patients seeking a bariatric surgery weight reduction procedure have non-alcoholic fatty liver disease (NAFLD), while a smaller subset of patients withi...

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

The purpose of the present study is to assess the effects of LMB763 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH

Companies [1654 Associated Companies listed on BioPortfolio]

HARVEY NASH GROUP

Harvey Nash was founded in London in 1988. David Higgins, the current Executive Vice Chairman, was one of the original founders and still has a sizeable financial stake in the company. Early on, the m...

Nash Finch Company

Patricia Nash

The quintessential embodiment of style, form and function, Patricia Nash Designs creates handbags and accessories that are made of beautiful, vegetable tanned Italian leather. The...

Harvey & Company LLC

Harvey & Company has a long track record of successful investments and acquisitions across a variety of manufacturing, business service and distribution sectors. Our success is based on the recognitio...

North American Specialty Hospital

Headquartered in Denver, NASH is a US majority-owned and managed enterprise. Incorporating US physicians in its service delivery, NASH is designed to provide pre-operative and pos...

More Information about "HARVEY NASH GROUP" on BioPortfolio

We have published hundreds of HARVEY NASH GROUP news stories on BioPortfolio along with dozens of HARVEY NASH GROUP Clinical Trials and PubMed Articles about HARVEY NASH GROUP for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of HARVEY NASH GROUP Companies in our database. You can also find out about relevant HARVEY NASH GROUP Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record